What India can learn from Kinvard Bio

When penicillin was approved for widespread use in the 1940s, it changed the rules of medicine. Scientists involved in its development won Nobel Prizes. For the first time in human history, infections that had reliably killed people stopped reliably killing people.

That position is gone. AMR is now responsible for around 1.27 million deaths a year directly, and contributes to nearly 4.95 million more, according to World Health Organization (WHO) data. Projections to 10 million annual deaths by 2050 are now the working assumption in serious policy conversations. The pipeline that produced the original generation of antibiotics has not been refilled. New antibacterial classes have been arriving at a pace that does not match the rate at which resistance is moving against the old ones.

Kinvard Bio is one of the few companies seriously trying to change that. It started as a scientific spinout from the Andrew Myers lab at Harvard. The programme is centred on oxepanoprolinamides (OPPs), a class of ribosome-targeting antibiotics designed to bind the bacterial ribosome in a structurally distinct way, with potential activity against pathogens that have already developed resistance to existing antibiotics. The science is real. It is also early. Most discovery-stage antibiotic programmes do not make it through.

What makes Kinvard interesting is not only the science, though. It is the funding architecture around it. The company has received non-dilutive funding from CARB-X, the public-private partnership that finances early-stage antibacterial development at scale. CARB-X grants are typically in the multi-million-dollar range and are designed specifically to bridge the gap that traditional venture capital will not cross. Alongside CARB-X, Kinvard is backed by specialist investors who understand that antibiotic discovery runs on long timelines, high failure rates, and an uncertain commercial market. Those investors are not common. They exist because the surrounding system makes them possible.

That is the part of the story that should travel.

The paradox in India

India carries one of the world's heaviest burdens of antimicrobial resistance. It is also among the world's largest pharmaceutical manufacturers. The industry has built deep capability in reverse-engineering complex molecules, producing high-quality generics, and competing on cost at global scale. It has not produced a meaningful number of venture-backed start-ups dedicated to discovering entirely new antibiotic classes. There is genuine work happening. Bugworks is developing new-class antibacterials targeting Gram-negative resistance. Orchid and Wockhardt have antimicrobial programmes with international visibility. C-CAMP and similar translational platforms are doing serious early-stage work. The pattern overall is good, but thin against the size of the resistance problem India is sitting on.

Antibiotic discovery is inherently risky. New classes need years of fundamental research, microbiology programmes, and translational work before they get anywhere near clinical trials. The probability of failure is high. The commercial market for antibiotics is structurally weak, because stewardship deliberately constrains volume. The combined effect is that early-stage capital has flowed elsewhere: diagnostics, digital health, CDMOs, biosimilars. All of those are reasonable bets. None of them are the bet India most needs to make on AMR.

What enables a Kinvard

Three things had to be in place for Kinvard to exist as a company.

First, an academic laboratory capable of producing novel antibiotic scaffolds. The Myers lab represents thirty years of accumulated chemistry expertise in ribosome-targeting compounds. Universities are where this kind of programme starts.

Second, venture capital willing to back high-risk biomedical science with long timelines. That capital exists in the US partly because there are exits, and partly because the regulatory and reimbursement structure is more predictable. Some of it exists in Europe for similar reasons.

Third, a public-interest accelerator that derisks the early stage. CARB-X is the working example. Its role is to take a programme from interesting science to credible preclinical candidate without forcing the company to dilute itself to a level that destroys its eventual returns.

In India, two of those three exist in working form. The academic and translational layer is real, even if it is under-resourced. Public-interest accelerator capacity is starting to emerge. The missing piece is venture capital that will write the cheque to a high-risk antibiotic discovery programme without waiting for a US precedent to clear first. That is not a money problem. It is a confidence problem.

The pull-incentive question

The standard policy answer to the antibiotic-investment gap is the Western pull-incentive stack: subscription models like the UK's NICE pilot, guaranteed-availability payments, milestone-based revenue, the proposed US PASTEUR Act. These are useful experiments and they prove the gap is real. They will not transplant cleanly into India. The institutional plumbing they assume, large public payers, structured pull contracts, advance market commitments, is not the system Indian pharma operates inside.

India needs its own version of pull, designed for an Indian payer mix, an Indian procurement structure, and an Indian distributor network. That is harder to design than copying the US template. It is also the only version that will actually work here.

Philanthropic capital has a role to play in AMR R&D funding and will continue to. Philanthropy is not, however, going to replace the scale of commercial investment the field needs. If private investors decide that AMR is economically irrational, no amount of grant money is going to fill that gap.

What this requires is coordinated work across academic technology transfer, dedicated antibiotic-stage venture funding, India-shaped pull incentives, and clearer regulatory pathways for novel-class antimicrobials. Building that is not only an industrial agenda. It is a public-health agenda for a country sitting at the centre of the global resistance crisis.

Kinvard Bio is not the model India needs to copy. It is the proof that the model can exist. The question is whether India is ready to build its own version of it.

About the author

A second generation leader, is the executive director of Venus Remedies Limited and CEO of the Venus Medicine Research Center (VMRC), the R&D arm of Venus Remedies Limited. He represents a new generation of healthcare entrepreneurs integrating deep-tech into pharmaceutical innovation. With an MSc in Experimental and Translational Therapeutics from the University of Oxford, he is driving a research-led, technology-first approach to drug development. Chaudhary has to his credit more than 10 scientific papers in reputed international journals.